{
    "root": "5844f950-ed79-43de-a6c4-2233878a9222",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Saxagliptin",
    "value": "20250228",
    "ingredients": [
        {
            "name": "SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE",
            "code": "4N19ON48ZN"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 200",
            "code": "5XDI2TS1EZ"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": "saxagliptin tablets dipeptidyl peptidase-4 ( dpp-4 ) inhibitor indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus . ( 1.1 ) limitations : • recommended treatment type 1 diabetes mellitus diabetic ketoacidosis . ( 1.2 )",
    "contraindications": "• recommended 2.5 mg 5 mg orally daily taken regardless meals . ( 2.1 ) • patients egfr < 45 ml/min/1.73 2 ( moderate severe renal impairment , end-stage renal disease ) : recommended 2.5 mg daily regardless meals . ( 2.2 ) • assess renal function starting saxagliptin tablets periodically thereafter . ( 2.2 ) • limit saxagliptin tablets 2.5 mg daily patients also taking strong cytochrome p450 3a4/5 ( cyp3a4/5 ) inhibitors ( e.g . , ketoconazole ) . ( 2.3 )",
    "warningsAndPrecautions": "supplied saxagliptin tablets available containing 3.075 mg 6.149 mg saxagliptin hydrochloride dihydrate equivalent 2.5 mg 5 mg saxagliptin . 2.5 mg tablets yellow , film-coated , round , unscored tablets imprinted sx1 black ink one side tablet blank side . available follows : ndc 0378-4705-93bottles 30 tablets ndc 0378-4705-77bottles 90 tablets 5 mg tablets white off-white , film-coated , round , unscored tablets imprinted sx2 black ink one side tablet blank side . available follows : ndc 0378-4706-93bottles 30 tablets ndc 0378-4706-77bottles 90 tablets storage handling store 20° 25°c ( 68° 77°f ) . [ usp controlled room temperature . ] dispense tight , light-resistant container defined usp using child-resistant closure . pharmacist : dispense medication guide prescription .",
    "adverseReactions": "saxagliptin tablets contraindicated patients history serious hypersensitivity reaction saxagliptin ingredients saxagliptin tablets . anaphylaxis , angioedema , exfoliative skin conditions reported saxagliptin tablets [ ( 5.4 ) ( 6.2 ) ] .",
    "indications_original": "Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 ) Limitations of use: • Not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1.2 )",
    "contraindications_original": "• Recommended dosage is 2.5 mg or 5 mg orally once daily taken regardless of meals. ( 2.1 ) • Patients with an eGFR < 45 mL/min/1.73 m 2 (moderate or severe renal impairment, or end-stage renal disease): Recommended dosage is 2.5 mg once daily regardless of meals. ( 2.2 ) • Assess renal function before starting saxagliptin tablets and periodically thereafter. ( 2.2 ) • Limit the dosage of saxagliptin tablets to 2.5 mg daily for patients also taking strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole). ( 2.3 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Saxagliptin Tablets are available containing 3.075 mg or 6.149 mg of saxagliptin hydrochloride dihydrate equivalent to 2.5 mg or 5 mg of saxagliptin.\n                  The 2.5 mg tablets are yellow, film-coated, round, unscored tablets imprinted with SX1 over M in black ink on one side of the tablet and blank on the other side. They are available as follows:\n                  NDC 0378-4705-93bottles of 30 tablets\n                  NDC 0378-4705-77bottles of 90 tablets\n                  The 5 mg tablets are white to off-white, film-coated, round, unscored tablets imprinted with SX2 over M in black ink on one side of the tablet and blank on the other side. They are available as follows:\n                  NDC 0378-4706-93bottles of 30 tablets\n                  NDC 0378-4706-77bottles of 90 tablets\n                  \n                     Storage and Handling\n                  \n                  \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] \n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  \n                     PHARMACIST: Dispense a Medication Guide with each prescription.",
    "adverseReactions_original": "Saxagliptin tablets are contraindicated in patients with a history of a serious hypersensitivity reaction to saxagliptin or any of the ingredients in saxagliptin tablets. Reactions such as anaphylaxis, angioedema, or exfoliative skin conditions have been reported with saxagliptin tablets [see Warnings and Precautions (5.4) and Adverse Reactions (6.2)\n                     ]."
}